IL123294A0 - Monoclonal antibody BR110 and uses thereof - Google Patents

Monoclonal antibody BR110 and uses thereof

Info

Publication number
IL123294A0
IL123294A0 IL12329496A IL12329496A IL123294A0 IL 123294 A0 IL123294 A0 IL 123294A0 IL 12329496 A IL12329496 A IL 12329496A IL 12329496 A IL12329496 A IL 12329496A IL 123294 A0 IL123294 A0 IL 123294A0
Authority
IL
Israel
Prior art keywords
antigen
monoclonal antibody
complex
ligands
ligand
Prior art date
Application number
IL12329496A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL123294A0 publication Critical patent/IL123294A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL12329496A 1995-10-19 1996-10-07 Monoclonal antibody BR110 and uses thereof IL123294A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US564195P 1995-10-19 1995-10-19
PCT/US1996/016070 WO1997014796A1 (en) 1995-10-19 1996-10-07 Monoclonal antibody br110 and uses thereof

Publications (1)

Publication Number Publication Date
IL123294A0 true IL123294A0 (en) 1998-09-24

Family

ID=21716930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12329496A IL123294A0 (en) 1995-10-19 1996-10-07 Monoclonal antibody BR110 and uses thereof

Country Status (11)

Country Link
US (1) US5840854A (xx)
EP (1) EP0856054B1 (xx)
JP (1) JP2001501801A (xx)
AT (1) ATE265532T1 (xx)
AU (1) AU7394296A (xx)
CA (1) CA2235269C (xx)
DE (1) DE69632333T2 (xx)
ES (1) ES2219699T3 (xx)
IL (1) IL123294A0 (xx)
NO (1) NO321548B1 (xx)
WO (1) WO1997014796A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6366762B1 (en) * 1999-03-31 2002-04-02 Qualcomm, Inc. System and method for measuring round trip delay on the paging and access channels
US6617432B1 (en) * 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20030009781A1 (en) * 2001-03-29 2003-01-09 Allen Keith D. Transgenic mice containing Kir3.3 potassium channel gene disruptions
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
CN101264325B (zh) 2002-03-01 2017-03-01 免疫医疗公司 Rs7抗体
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
JP4689521B2 (ja) * 2006-04-07 2011-05-25 財団法人電力中央研究所 抗鉛モノクローナル抗体
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
CA2752510C (en) 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3135302A1 (en) 2009-12-02 2017-03-01 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
JP5859434B2 (ja) * 2010-05-17 2016-02-10 株式会社カイオム・バイオサイエンス ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
WO2011155579A1 (ja) * 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
MX2016010683A (es) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
US20210316003A1 (en) 2020-03-20 2021-10-14 Immunomedics, Inc. Biomarkers for sacituzumab govitecan therapy
WO2022078424A1 (zh) 2020-10-14 2022-04-21 上海翰森生物医药科技有限公司 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途
CN117295524A (zh) 2021-06-02 2023-12-26 百奥泰生物制药股份有限公司 药物偶联物及其用途
AU2022350725A1 (en) 2021-09-23 2024-03-28 Changzhou Hansoh Pharmaceutical Co., Ltd. Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof
AU2023241225A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
DE69027210T2 (de) * 1989-04-21 1997-01-23 Protein Design Labs, Inc., Palo Alto, Calif. Rekombinantes antikörper-toxin-fusion-protein
CA2120507A1 (en) * 1991-10-18 1993-04-29 Alban J. Linnenbach Soluble variants of type 1 membrane proteins, and methods of using them

Also Published As

Publication number Publication date
DE69632333T2 (de) 2004-12-30
DE69632333D1 (de) 2004-06-03
AU7394296A (en) 1997-05-07
EP0856054A1 (en) 1998-08-05
NO981745D0 (no) 1998-04-17
NO321548B1 (no) 2006-05-29
NO981745L (no) 1998-04-17
CA2235269C (en) 2006-09-19
EP0856054B1 (en) 2004-04-28
US5840854A (en) 1998-11-24
JP2001501801A (ja) 2001-02-13
WO1997014796A1 (en) 1997-04-24
ES2219699T3 (es) 2004-12-01
MX9802129A (es) 1998-05-31
CA2235269A1 (en) 1997-04-24
ATE265532T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
IL123294A0 (en) Monoclonal antibody BR110 and uses thereof
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
EP0724456A4 (en) ANTIBODIES AGAINST CD40
AU2001257012A1 (en) Methods for selective targeting
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
AU688953B2 (en) Determination of a specific immunoglobulin using multiple antigens
CA2442182A1 (en) Modulation of pd-1 interactions with its ligands
WO2004025248A3 (en) Antibody pair screening methods
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
DE69433114D1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
AU4441799A (en) Monoclonal antibodies that recognize antigens associated with tumor metastasis
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
IL108607A0 (en) Preparation of photoprotein conjugates and methods of use thereof
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
GB9623531D0 (en) Sheets,kits and methods for detecting antigens or antibodies
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
NO20001051D0 (no) Monoklonale antistoffer som binder testosteron
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
Loy et al. Correspondence re: TS Loy, AA Diaz-Arias, JT Bickel. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases. Mod Pathol 3: 294, 1990